Japanese Antibody Firm Signs Agreement On Cancer Diagnosis Through Urine Samples
This article was originally published in PharmAsia News
Kumamoto, Japan-based antibody maker, Trans Genic, announced July 8 that it had signed a licensing agreement with a test agent maker looking to make cancer diagnosis through urine samples. Until now, the licensee company has conducted clinical trials based on Trans Genic's research results, with a goal toward commercialization and obtaining manufacturing and marketing approval. It is said that the development has shown promising results. According to the agreement, Trans Genic will continue to charge to provide necessary antibodies for clinical development and production, and will receive milestone fees and royalties based on sales after the product is marketed and launched. (Click here for more - Japanese language
You may also be interested in...
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.